Zusduri sales surge as UroGen nears Q4 profitability
- UroGen is a two-product commercial biotech with growing U.S. revenue from Jelmyto and Zusduri.
- Total revenue hit $89 million in the third quarter of 2026, driven by a rapid product launch.
- Zusduri generated $68 million in the third quarter, representing 35 percent sequential growth.
- The FDA set a June 2027 action date for the next-generation drug UGN-103.
- Management expects the company to reach profitability and positive cash flow in the fourth quarter of 2026.
A launch that must carry the company
UroGen relies on the success of Zusduri. The drug replaces some repeat surgeries with local chemoablation, which places medicine directly in the bladder to destroy tumor tissue.
The launch continued to accelerate in the third quarter of 2026. Zusduri revenue reached $68 million, representing 35 percent sequential growth. Repeat prescribers now make up half of total writers, showing that doctors are adopting the treatment. Management expects this growth to push the company into profitability by the end of 2026.
The pipeline is also advancing. The FDA accepted the new drug application for UGN-103 and set a review target date of June 14, 2027. This drug will extend the franchise and reset patent protection to 2044.
The bear case highlights execution risk and valuation. The stock trades at a premium, scoring low on valuation metrics. The company carries a $250 million loan, and total success depends on scaling one primary product. Any slowdown in community practice adoption could derail the story.
RTGel turns dwell time into a product
UroGen bases its platform on RTGel. This reverse-thermal hydrogel is liquid when given and then turns into a gel at body temperature. The goal is simple: keep cancer medicine in contact with urinary tract tissue for longer.
The company makes money from U.S. product sales of Jelmyto and Zusduri. Jelmyto treats low-grade upper tract urothelial cancer. Zusduri treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the main growth driver.
UroGen is expanding beyond urology. A new collaboration gives them access to a platform for treating solid tumors, including an option for a cisplatin gel targeting head and neck cancer.
This model can scale if urologists use the drugs often and payers keep paying without delays. It can break if community practices avoid the workflow or if single-source suppliers fail to deliver key compounds.
Two commercial drugs and a growing pipeline
Zusduri
Zusduri is the main value driver. It generated $68 million in third-quarter 2026 revenue and has patent protection into 2044.
Jelmyto
Jelmyto is approved for adults with low-grade upper tract urothelial cancer. It produced $21 million of revenue in the third quarter of 2026.
UGN-103
UGN-103 is a next-generation RTGel formulation. The FDA set a review action date of June 14, 2027, for its new drug application.
UGN-104
UGN-104 is another RTGel-based formulation. It is currently in Phase 3 clinical trials.
UGN-501
UGN-501 is an investigational virus designed to attack cancer cells. A Phase 1 trial dosed its first patient, with initial data expected in 2027.
Cisplatin gel
Acquired through a collaboration, this Phase 2-ready therapy targets advanced head and neck cancer, moving UroGen beyond urology.
Revenue depends heavily on one product
UroGen reports one operating segment. In the third quarter of 2026, Zusduri made up 76 percent of the $89 million total product revenue, with the remainder from Jelmyto.
What could break the thesis
Zusduri growth slows down
High impact · Medium oddsThe company depends entirely on the Zusduri launch. If community practice adoption slows or repeat utilization drops, revenue growth could stall.
Jelmyto faces clinical competition
Medium impact · Medium oddsJelmyto is seeing increased competition for eligible patients from ongoing clinical trials in the low-grade space. This creates headwinds for new patient starts and can limit revenue.
UGN-103 faces regulatory delays
Medium impact · Medium oddsUGN-103 is important because it extends the franchise and resets patent protection. The FDA has set a June 2027 target date, but any delay or rejection would weaken the bridge to the next cycle.
Supplier concentration bites
Medium impact · Low oddsUroGen relies on single-source suppliers for key compounds. A supply issue could limit product availability right when the launch needs clean execution.
Debt covenant restrictions
Medium impact · Low oddsThe company must follow restrictive covenants under its $250 million loan facility. Failure to meet these terms could restrict future operations or harm financial health.
In one breath
What does UroGen Pharma do?
UroGen develops and sells cancer treatments for the urinary tract. Its core technology, RTGel, helps medicine stay in contact with tissue for longer.
Why is Zusduri important for URGN stock?
Zusduri is the main growth driver. It produced $68 million of third-quarter 2026 revenue and is pushing the company toward profitability.
When will UGN-103 be approved?
The FDA accepted the application for UGN-103 and set a review target date of June 14, 2027.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near UroGen Pharma Ltd. in Finn's Biotechnology industry ranking.

